POWERFUL
Eliminates pain1
PRESCRIBE UBRELVY® TO TREAT MIGRAINE ATTACKS WHEN HEAD PAIN SPIKES OR BEFORE IT STRIKES1
Real UBRELVY patient.
WHEN HEAD PAIN SPIKES
21% of patients experienced pain freedom at 2 hours (co-primary endpoint)*
UBRELVY 100 mg (95/448) vs 12% placebo (54/456)1,3
RAPID
Relieves pain quickly1
61% of patients experienced pain relief at 2 hours (secondary endpoint)*
UBRELVY 100 mg (275/448) vs 49% placebo (224/456)1,4
BEFORE HEAD PAIN STRIKES
HEAD PAIN AVOIDANCE
UBRELVY has demonstrated prodrome data for treatment early in the migraine attack from a phase 3 clinical trial5
Data on patients who avoided moderate to severe headache pain, when UBRELVY 100 mg was taken during prodrome5
UBRELVY IS THE FIRST AND ONLY ACUTE TREATMENT FOR MIGRAINE WITH DEMONSTRATED PRODROME DATA IN A PHASE 3 CLINICAL TRIAL5†
*In pivotal clinical studies, patients took UBRELVY within 4 hours of migraine headache onset.6
†The prodrome study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, crossover study in which the prodrome phase was defined as 1-6 hours prior to onset of headache.5 For additional details, see prodrome study design pop-up above.
Data presented above are in reference to UBRELVY 100 mg only. See similar results for patients taking UBRELVY 50 mg.7
See ACHIEVE pivotal trials design pop-up above for more details, including additional co-primary endpoint data.
56% of commercially insured lives are unrestricted or require 0 to 1 prior therapy to access UBRELVY3‡§
More on national access
Discover plans in your area that cover UBRELVY
More on local access
With the UBRELVY Complete Savings Card, eligible commercially insured patients may pay as little as $0II a month for UBRELVY
Help patients save‡Managed Markets Insight & Technology, LLCTM, a trademark of MMIT. Data as of December 2024 and subject to change.
Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits are determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. AbbVie does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.
§Unrestricted implies no step edit.
IIEligibility: Available to patients with commercial insurance coverage for UBRELVY who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs), or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit UBRELVY.com/savings-terms or call 1-844-482-7358 for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy.
